Key takeaway: Lupin Limited reported a record Q1 FY2027 earnings conference call on August 7, 2026, highlighting total revenues exceeding INR 8,000 crores and EBITDA surpassing INR 2,400 crores for the first time. Management noted a 16th consecutive quarter of year-on-year growth, with strong contributions from the U.S. and a 20% plus organic revenue growth outside the U.S. The U.S. business is projected to reach USD 1.1 billion to USD 1.2 billion for the year, despite increased competition in key products. The India business grew 13.9% year-on-year, with a focus on increasing the chronic segment's share. Emerging markets saw a 52% growth, particularly in Brazil. Management reiterated a guidance of high single-digit revenue growth and EBITDA margins around 25% for the year, while expressing optimism about future growth and innovation initiatives.

Key takeaway: Lupin Limited's investor presentation for Q1 FY27 reported strong financial performance, with sales reaching INR 82,172 million, a 33% year-over-year increase. The presentation highlighted a net income of INR 14,150 million and an EBITDA of INR 24,635 million, reflecting a 50% growth. Key growth metrics included significant contributions from various regions, with North America showing a 43% increase in sales. The company announced several product approvals and launches, including EMA approval for NaMuscla® and entry into the Chinese market with Oseltamivir Phosphate. Management emphasized a focus on innovation, with plans to launch over 20 products in FY27 and a commitment to maintaining high-quality standards across manufacturing sites. The presentation also noted Lupin's sustainability achievements and recognition in ESG ratings, reinforcing its commitment to corporate responsibility.

Key takeaway: Lupin Limited's investor presentation for Q1 FY27 reported strong financial performance, with sales reaching INR 82,172 million, a 33% year-over-year increase. The presentation highlighted a net income of INR 14,150 million and an EBITDA of INR 24,635 million, reflecting growth of 16% and 50% respectively. Key developments included regulatory approvals for several products and a focus on expanding the product pipeline, particularly in the U.S. and India. The company emphasized its commitment to quality and compliance, noting successful FDA inspections and ongoing remediation efforts. Additionally, Lupin's sustainability initiatives were showcased, including recognition in global ESG rankings and various awards for its environmental efforts. The presentation outlined plans for future product launches and market expansion, particularly in chronic care and innovative therapies.

Key takeaway: Lupin Limited's Q4 FY2026 earnings conference call highlighted the company's 15th consecutive quarter of year-over-year growth, achieving record sales and profitability. Management reported a 40% year-over-year growth in the U.S. business, driven by new product launches, including Tolvaptan and Mirabegron. The India business grew 11.5% year-over-year, with the core prescription segment growing 14.5%. Emerging markets saw a 49% growth, particularly in Brazil. R&D expenditure was 8% of sales, focusing on complex and specialty products. Management set a goal for FY27 of high-single digit revenue growth with EBITDA margins around 25%. The company emphasized its commitment to quality and compliance, alongside a strong innovation pipeline. The earnings call concluded with management expressing confidence in sustaining growth despite potential headwinds from competition and geopolitical uncertainties.

Key takeaway: Lupin Limited's investor presentation for Q4 FY26 reported strong financial performance, with net sales reaching INR 73,919 million, reflecting a 33% year-over-year growth. The company achieved an EBITDA of INR 21,711 million and a net income of INR 14,604 million, marking increases of 68% and 89% respectively compared to the previous year. Key developments included the completion of the acquisition of VISUfarma B.V. and several product approvals and launches in various markets. The presentation highlighted growth in the India business, with a 14.5% increase in the Rx segment, and noted the company's focus on expanding its specialty pharma footprint and enhancing manufacturing capabilities. Additionally, Lupin emphasized its commitment to sustainability and quality, achieving significant milestones in ESG ratings and regulatory compliance. The document outlined a strategic plan for future growth, including new product launches and market expansions.

Key takeaway: Lupin Limited's Q3 FY2026 earnings conference call highlighted strong performance, with revenue surpassing previous records and marking the 14th consecutive quarter of year-on-year growth. Management reported broad-based growth across regions, particularly in the US, where new product launches, including Tolvaptan and Risperdal Consta®, contributed significantly. The company achieved a 46% year-on-year growth in US sales, while India saw a 5.6% increase, driven by the core prescription business. Management emphasized a focus on expanding complex products and specialty portfolios, with over 50 active products in the pipeline. EBITDA margins improved to 31.1%, reflecting strong operational performance. The company also received positive compliance updates and maintained a commitment to sustainability, achieving high ratings for climate change and water security. Overall, management expressed optimism about future growth prospects and strategic initiatives.